The immune thrombocytopenia market attained a value of USD 3.01 Billion in 2025 driven by the advancements in targeted therapies across the 8 major markets. It is expected to grow at a CAGR of 3.90% in the forecast period of 2026-2035 and reach a market value of USD 4.41 Billion by 2035.
Base Year
Historical Period
Forecast Period
Increasing incidence of autoimmune disorders and advancements in immune thrombocytopenia therapies are propelling the growth of the market. Growing importance of patient-centric therapies and targeted drug advancements are also boosting the market growth.
Rise in research initiatives is one of the major market trends. For instance, in June 2024, Mezagitamab an experimental drug by Takeda, displayed encouraging outcomes in immune thrombocytopenia. This progress signifies the consistent dedication to novel therapeutics driving clinical improvements and expanding market access.
The United States is expected to dominate the market due to heavy investments in research operations, high incidence rates, and advanced healthcare infrastructure.
Compound Annual Growth Rate
3.9%
Value in USD Billion
2026-2035
*this image is indicative*
Immune thrombocytopenia is an autoimmune disease characterized by the immune system destroying the body's platelets. Excessive reduction in platelet count can lead to severe bruising, bleeding gums, and internal bleeding issues may arise. The condition can occur in adults and children and may be considered acute or chronic, based on the duration of symptoms and frequency of relapses. The market is driven by growing awareness, emphasis on early diagnostics, and treatment of the condition. A rise in the geriatric population can also be considered a major factor driving the growth of the market.
Growing Prevalence of Related Autoimmune Disorders
Immune thrombocytopenia can be associated with other autoimmune diseases such as lupus and rheumatoid arthritis. The 2023 NCBI report indicated that lupus has a prevalence rate of 72.1 to 74.4 per 100,000 individuals, with an incidence rate of 5.6 per 100,000 person-years. The rise in autoimmune disorders can contribute to significant market growth in the forecast period.
Rise in Research Initiatives and Clinical Trials to Meet Rising Immune Thrombocytopenia Market Demand
In June 2024 , Takeda Pharmaceuticals reported that mezagitamab, an experimental drug, showed encouraging outcomes in Phase 2b trials for immune thrombocytopenia. The experiments demonstrated that mezagitamab, when given subcutaneously in different amounts, elevated the platelet levels and the effect lasted for weeks after treatment. This study occurred at various sites and evaluated the safety and effectiveness in individuals suffering from chronic or persistent immune thrombocytopenia. Increasing research activities by leading companies is one of the notable market trends, expected to impact the market positively.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
“Immune Thrombocytopenia Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Disease Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Chronic Segment is Anticipated to Undergo Substantial Growth in the Share by Disease Type
Based on disease type, the market is divided into acute and chronic immune thrombocytopenia. Among these, the chronic segment is expected to dominate the market as it needs extensive treatment and management. Unlike acute immune thrombocytopenia, chronic immune thrombocytopenia demands continuous therapeutic focus. Thus, there is a focus on speeding up research, significantly impacting the immune thrombocytopenia treatment landscape.
Market Segmentation Based on the Route of Administration Set to Witness Substantial Growth
The market segmentation by route of administration includes orals and injectables. Out of these, oral treatments are expected to lead the market as they are easy to use, convenient, and help patients stick to their medication plans, especially those needing long-term treatment. Oral treatments are becoming more popular for chronic immune thrombocytopenia as patients prefer an easier route of administration.
The market is segmented by region including the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. Among these, the United States is expected to dominate the market share which can be attributed to the high incidence of the condition along with substantial funding and investment for research. The market in this region is influenced by factors such as a growing elderly population and lifestyle-related risks. Government support and a strong healthcare system boost market growth by leading clinical trials and discovering treatments like targeted therapies and immunotherapies. There is also a rising emphasis on early diagnosis and personalized treatments, which fuels growth further. Europe also holds a considerable market share, owing to the presence of numerous research and academic institutions.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Pfizer, founded in 1849 and based in New York City is one of the leading pharmaceutical companies globally. The company has a strong focus on immunology and hematology. In the immune thrombocytopenia market, Pfizer offers Tavalisse (fostamatinib), an oral spleen tyrosine kinase (SYK) inhibitor for treating chronic immune thrombocytopenia in adults. The company continues to invest in research and development to expand its immune thrombocytopenia treatment pipeline, including novel biologics and immunotherapies to improve patient outcomes.
Founded in 1896 and headquartered in Basel, Switzerland, Roche’s portfolio includes MabThera/Rituxan (rituximab), a monoclonal antibody used for patients with refractory immune thrombocytopenia. This treatment targets CD20-positive B-cells and has proven effective for chronic immune thrombocytopenia patients.
Founded in 1980 and based in Thousand Oaks, California, Amgen is known for its biologics that treat hematology and autoimmune diseases. The company offers Nplate (romiplostim), a thrombopoietin receptor agonist that helps increase platelet counts in adults with chronic immune thrombocytopenia.
Founded in 1996 and based in Basel, Switzerland, Novartis offers Promacta (eltrombopag), a thrombopoietin receptor agonist used for treating chronic immune thrombocytopenia in adults and children unresponsive to other treatments. Promacta is available in oral and pediatric formulations, making it suitable for different age groups and treatment needs.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Rigel Pharmaceuticals, Inc., Dova Pharmaceuticals Inc., Grifols S.A, CSL Limited, Octapharma AG, Intas Pharmaceuticals Ltd., and Saol Therapeutics.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Disease Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share